collection-container
gateway-splitter
collection-item-type
core-card, core-text
collection-container-variant
tinted
headline

Select a condition below to discover a combination therapy to target HER2

Card_identifier
Image_caption
Not real patients.
heading

HER2+ metastatic breast cancer (MBC)

body
TUKYSA (tucatinib) is a prescription medicine used with the medicines trastuzumab and capecitabine to treat adults with human epidermal growth factor receptor-2 (HER2) positive breast cancer that has spread to other parts of the body such as the brain (metastatic), or that cannot be removed by surgery, and who have received one or more anti-HER2 breast cancer treatments.

It is not known if TUKYSA is safe and effective in children.
cta
Enter site
Card_identifier
Image_caption
Not real patients.
heading

RAS wild-type, HER2+ metastatic colorectal cancer (mCRC)

body
TUKYSA (tucatinib) is a prescription medicine used with the medicine trastuzumab to treat adults with RAS wild-type human epidermal growth factor receptor-2 (HER2) positive colorectal cancer that has spread to other parts of the body (metastatic), or cannot be removed by surgery, and who have received treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy and it did not work or is no longer working.

This use is approved based on a clinical study that measured how many patients had a tumor response and how long that response lasted. Studies are ongoing to confirm the benefit of TUKYSA for this use.

It is not known if TUKYSA is safe and effective in children.
cta
Enter site